Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customersâ research, therapeutic and vaccine programs. This segmentâs business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segmentâs business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļMRVI
āļāļ·āđāļāļāļĢāļīāļĐāļąāļMaravai LifeSciences Holdings Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļNov 20, 2020
āļāļĩāļāļĩāđāļBrust (Bernd)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ570
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļNov 20
āļāļĩāđāļāļĒāļđāđ10770 Wateridge Circle Suite 200
āđāļĄāļ·āļāļSAN DIEGO
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ92121
āđāļāļĢāļĻāļąāļāļāđ18585460004
āđāļ§āđāļāđāļāļāđhttps://www.maravai.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļMRVI
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļNov 20, 2020
āļāļĩāļāļĩāđāļBrust (Bernd)
Mr. Bernd Brust
Chief Executive Officer, Director
Chief Executive Officer, Director
Mr. Rajesh J. (Raj) Asarpota
Mr. Rajesh J. (Raj) Asarpota
Chief Financial Officer
Mr. Kurt Oreshack
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
Mr. Robert Andrew (Andy) Eckert
Mr. Robert Andrew (Andy) Eckert
Independent Chairman of the Board
Independent Chairman of the Board
Ms. Christine Dolan
Executive Vice President, General Manager - Cygnus Technologies
Executive Vice President, General Manager - Cygnus Technologies
Mr. Gregory T. (Greg) Lucier
Mr. Gregory T. (Greg) Lucier
Independent Director
Ms. Susannah Gray
Independent Director
Mr. Luke Joseph Marker
Director
Dr. John A. Deford, Ph.D.
Dr. John A. Deford, Ph.D.
Independent Director
Mr. Sean L. Cunningham
Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Bernd Brust
Chief Executive Officer, Director
Chief Executive Officer, Director
Mr. Rajesh J. (Raj) Asarpota
Mr. Rajesh J. (Raj) Asarpota
Chief Financial Officer
Mr. Kurt Oreshack
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
Mr. Robert Andrew (Andy) Eckert
Mr. Robert Andrew (Andy) Eckert
Independent Chairman of the Board
Independent Chairman of the Board
Ms. Christine Dolan
Executive Vice President, General Manager - Cygnus Technologies
Executive Vice President, General Manager - Cygnus Technologies
Mr. Gregory T. (Greg) Lucier
Mr. Gregory T. (Greg) Lucier
Independent Director
Global X Genomics & Biotechnology ETF
Invesco Nasdaq Biotechnology ETF
ProShares Ultra Nasdaq Biotechnology
iShares Biotechnology ETF
Invesco RAFI US 1500 Small-Mid ETF
iShares Russell 2000 Value ETF
Schwab U.S. Small-Cap ETF
Proshares Ultra Russell 2000
ProShares Hedge Replication ETF
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Global X Genomics & Biotechnology ETF
āļŠāļąāļāļŠāđāļ§āļ0.41%
Invesco Nasdaq Biotechnology ETF
āļŠāļąāļāļŠāđāļ§āļ0.05%
ProShares Ultra Nasdaq Biotechnology
āļŠāļąāļāļŠāđāļ§āļ0.04%
iShares Biotechnology ETF
āļŠāļąāļāļŠāđāļ§āļ0.03%
Invesco RAFI US 1500 Small-Mid ETF
āļŠāļąāļāļŠāđāļ§āļ0.03%
iShares Russell 2000 Value ETF
āļŠāļąāļāļŠāđāļ§āļ0.02%
Schwab U.S. Small-Cap ETF
āļŠāļąāļāļŠāđāļ§āļ0.01%
iShares Russell 2000 ETF
āļŠāļąāļāļŠāđāļ§āļ0.01%
Proshares Ultra Russell 2000
āļŠāļąāļāļŠāđāļ§āļ0.01%
ProShares Hedge Replication ETF
āļŠāļąāļāļŠāđāļ§āļ0.01%
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē

āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ